Genelux (NASDAQ:GNLX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

GNLX has been the topic of several other reports. Benchmark dropped their price target on Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Genelux in a research report on Monday, March 31st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $17.75.

Genelux Stock Down 1.5%

Shares of Genelux stock traded down $0.05 on Friday, hitting $3.38. 122,526 shares of the company's stock traded hands, compared to its average volume of 172,798. The stock has a market cap of $127.54 million, a P/E ratio of -3.84 and a beta of -0.34. The firm's 50-day moving average is $2.78 and its 200 day moving average is $3.15. Genelux has a 52-week low of $1.60 and a 52-week high of $5.89.

Genelux (NASDAQ:GNLX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. Equities research analysts forecast that Genelux will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Genelux

Large investors have recently added to or reduced their stakes in the stock. LPL Financial LLC grew its stake in shares of Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after purchasing an additional 39,516 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Genelux in the fourth quarter worth $41,000. Marshall Wace LLP grew its stake in shares of Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after purchasing an additional 52,958 shares in the last quarter. Advisor Resource Council bought a new position in shares of Genelux in the first quarter worth $34,000. Finally, 5T Wealth LLC bought a new position in shares of Genelux in the first quarter worth $49,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.